In this article Steve Lynn from Regulatory Compliance Associates discuss why the top 10 FDA Form 483 issues have remained mostly the same for the past twenty-three years and how the industry can solve these systemic repeat observations.
Published Article
PUBLISHED ARTICLE
A Discourse on Pharmaceutical cGMP FDA Form 483 Trends: Why are We Re-Living the Same Issues Over the Last 23 Years?
Published In: American Pharmaceutical Review
June 24, 2022
